Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma.
White MG, Szczepaniak Sloane R, Witt RG, Reuben A, Gaudreau PO, Andrews MC, Feng N, Johnson S, Class CA, Bristow C, Wani K, Hudgens C, Nezi L, Manzo T, De Macedo MP, Hu J, Davis R, Jiang H, Prieto P, Burton E, Hwu P, Tawbi H, Gershenwald J, Lazar AJ, Tetzlaff MT, Overwijk W, Woodman SE, Cooper ZA, Marszalek JR, Davies MA, Heffernan TP, Wargo JA. White MG, et al. Among authors: gershenwald j. Oncoimmunology. 2021 Nov 6;10(1):1992880. doi: 10.1080/2162402X.2021.1992880. eCollection 2021. Oncoimmunology. 2021. PMID: 34777916 Free PMC article.
A novel AKT3 mutation in melanoma tumours and cell lines.
Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. Davies MA, et al. Among authors: gershenwald je. Br J Cancer. 2008 Oct 21;99(8):1265-8. doi: 10.1038/sj.bjc.6604637. Epub 2008 Sep 23. Br J Cancer. 2008. PMID: 18813315 Free PMC article.
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Kim KB, Legha SS, Gonzalez R, Anderson CM, Johnson MM, Liu P, Papadopoulos NE, Eton O, Plager C, Buzaid AC, Prieto VG, Hwu WJ, Frost AM, Alvarado G, Hwu P, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Benjamin RS, Bedikian AY. Kim KB, et al. Melanoma Res. 2009 Feb;19(1):42-9. doi: 10.1097/CMR.0b013e328314b84a. Melanoma Res. 2009. PMID: 19430405 Clinical Trial.
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma.
Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Davies MA, et al. Among authors: gershenwald je. Clin Cancer Res. 2009 Dec 15;15(24):7538-7546. doi: 10.1158/1078-0432.CCR-09-1985. Clin Cancer Res. 2009. PMID: 19996208 Free PMC article.
Clinical correlates of NRAS and BRAF mutations in primary human melanoma.
Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA. Ellerhorst JA, et al. Clin Cancer Res. 2011 Jan 15;17(2):229-35. doi: 10.1158/1078-0432.CCR-10-2276. Epub 2010 Oct 25. Clin Cancer Res. 2011. PMID: 20975100 Free PMC article.
Targeted therapy for melanoma: a primer.
Davies MA, Gershenwald JE. Davies MA, et al. Surg Oncol Clin N Am. 2011 Jan;20(1):165-80. doi: 10.1016/j.soc.2010.09.003. Surg Oncol Clin N Am. 2011. PMID: 21111965 Free PMC article. Review.
415 results